课题基金 / 基金详情

COLLAGENASE IN THE TREATMENT OF DUPUYTREN'S DISEASE

COLLAGENASE IN THE TREATMENT OF DUPUYTREN'S DISEASE
胶原酶治疗掌腱膜挛缩症
批准号：
6123148
负责人：
LAWRENCE C HURST
金额：
$7.84万
依托单位：
STATE UNIVERSITY NEW YORK STONY BROOK
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6123148
关键词：
clinical research collagenase connective tissue connective tissue disorder connective tissue disorder chemotherapy contracture enzyme therapy fingers human subject human therapy evaluation limb movement

项目摘要

项目成果

LAWRENCE C HURST的其他基金

相似基金

相关文献

中文摘要
翻译
一项II期随机、安慰剂双盲试验正在研究注射胶原酶作为治疗手部固定屈曲挛缩畸形Dupuytren病的非手术治疗方法。这种治疗方法可以避免对Dupuytren病进行外科筋膜切除术。
英文摘要
A Phase II random, placebo double blind trial of injectable collagenase is being studied as a non-operative treatment for Dupuytren's disease, a fixed flexion contracture deformity of the hand. This therapy may obviate the need for surgical fasciectomy for Dupuytren's disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: STUDY OF THE RELATIVE SAFETY AND EFFICACY OF COLLAGENASE THERAPY
STUDY OF THE RELATIVE SAFETY AND EFFICACY OF COLLAGENASE THERAPY
STUDY OF THE RELATIVE SAFETY AND EFFICACY OF COLLAGENASE THERAPY
STUDY OF THE RELATIVE SAFETY AND EFFICACY OF COLLAGENASE THERAPY
海外基金